Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2237-2246

  Tockman, Melvyn S ^a,e   Mulshine, James L ^c   Piantadosi, Steven ^b   Erozan, Yener S ^b   Gupta, Prabodh K ^d   Ruckdeschel, John C ^e   Taylor, Philip R ^c   Zhukov, Tatyana ^a   Zhou, Wei Hong ^a   Qiao, You Lin ^c   Yao, Shu Xiang ^a,f  

^a The Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f Yunnan Tin Corporation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOPROTEIN;

ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MINING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINING; OCCUPATIONAL EXPOSURE; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SMOKING; SPUTUM; TIN; TREATMENT OUTCOME;

EID: 0031427367     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. U. S. Department of Health, Education, and Welfare. Smoking and Health. A report of the Surgeon General. Public Health Service. DHEW Publication No. PHS 79-50066, 1979.
2. Doll, R., and Peto, R. The causes of cancer. J. Natl. Cancer Inst., 66: 1191-1308, 1981.
3. American Cancer Society. Report on the cancer-related health check-up: cancer of the lung. CA Cancer J. Clin., 30: 199-207, 1980.
4. Peto, R., Lopez, A. D., Boreham, J., Thun, M., and Heath, C., Jr. Mortality from Smoking in Developed Countries 1950-2000. Indirect Estimates from National Vital Statistics. Oxford: Oxford University Press, 1994.
5. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics. CA Cancer J Clin., 46: 5-27, 1996.
6. Miller, B. A., Ries, L. A. G., Hankey, B. F., Kosary, C. L., Harras, A., Devesa, S. S., and Edwards, B. K. (eds.). SEER Cancer Statistics Review: 1973-1990. National Cancer Institute. NIH Publication No. 93-2789, 1993.
7. Strauss, G., DeCamp, M.. Dibiccaro, E., Richards, W., Harpole, D., Healey, E., and Sugarbaker, D. Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers. Proc. Amer. Soc. Clin. Oncol., 14: 362, 1995.
8. Burns, D. M. Tobacco smoking. In: J. M. Samet (ed.), Epidemiology of Lung Cancer, pp. 15-49. New York: Marcel Dekker, Inc., 1994.
9. Brown, C., and Chu, K. C. Use of multistage models to infer stage affected by carcinogenic exposure: example of lung cancer and cigarette smoking. J. Chron. Dis., 40 (Suppl. 2): 171s-179s, 1987.
10. Papadimitrakopoulou, V. A., and Hong, W. K. Biomarkers as intermediate endpoints in chemoprevention trials. In: Y. Martinet, N. Martinet, J. M. Vignaud, F. Hirsch, and J. L. Mulshine (eds.), Biological Basis of Lung Cancer Prevention, in press. Basel: Birkhauser Verlag AG, 1997.
11. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-25, 1997.
12. Evans, W. K., Will, B. P., Berthelot, J. M., and Wolfson, M. C. The economics of lung cancer management in Canada. Lung Cancer, 14: 19-29, 1996.
13. Tockman, M. S., Gupta, P. K., Myers, J. D., Frost, J. K., Baylin, S. B., Gold, E. B., Chase, A. M., Wilkinson, P. H., and Mulshine, J. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J. Clin. Oncol., 6: 1685-1693, 1988.
14. Mao, L., Hruban, R. H., Boyle, J. O., Tockman, M. S., and Sidransky, D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res., 54: 1634-1637, 1994.
15. Mao, L., Lee, D. J., Tockman, M. S., Erozan, Y. S., Askin, F., and Sidransky, D. Microsatellite alterations as clonal markers in the detection of human cancer. Proc. Natl. Acad. Sci. USA, 91: 9871-9875, 1994.
16. Zhou, J., Mulshine, J. L., Unsworth, E. J., Avis, I., Cuttitta, F., and Treston, A. Identification of a heterogeneous nuclear ribonucleoprotein (hnRNP) as an early lung cancer detection marker. J. Biol. Chem., 271: 10760-10766, 1996.
17. Burd, C. G., and Dreyfuss, G. Conserved structures and diversity of functions of RNA-binding proteins. Science, 265: 615-621, 1994.
18. Tockman, M. S., Erozan, Y. S., Gupta, P. K., Piantadosi, S., Mulshine, J. L., Ruckdeschel, J. C., and the LCEDWG Investigators. The early detection of second primary lung cancers by sputum immunostaining. Chest, 106: 385s-390s, 1994.
19. Grover, F. L., and Piantadosi, S. Recurrence and survival following resection of bronchioloalveolar carcinoma of the lung-The Lung Cancer Study Group experience. Ann. Surg., 209: 779-790, 1989.
20. Qiao, Y. L., Taylor, P. R., Yao, S. X., Schatzkin, A., Mao, B. L., Lubin, J., Rao, J. Y., Xuan, X. Z., Li, J. Y., and McAdams, M. The relation of radon exposure and tobacco use to lung cancer among miners in Yunnan Province, China. Am. J. Ind. Med., 16: 511-521, 1989.
21. Piantadosi, S. Long term follow-up of surgically resected T1N0 non-small cell lung cancer patients. Lung Cancer, 4 (Suppl.): A82, 1988.
22. Feld, R., Rubinstein, L. V., and Weisenberger, T. H. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J. Clin. Oncol., 2: 1352-1358, 1984.
23. Ginsberg, R. J. Limited resection for peripheral T1N0 tumors. Lung Cancer, 4 (Suppl.): A80, 1988.
24. Thomas, P., and Feld, R. Preliminary report of clinical trial comparing post-resection adjuvant chemotherapy versus no therapy for T1N1, T2N0 non-small cell lung cancer. Lung Cancer, 4 (Suppl.): A160, 1988.
25. Mountain, C. F. A new international staging system for lung cancer. Chest, 89: 225s-233s, 1986.
26. Kreyberg, L. Histological typing of lung tumors. Vol. 1, International Histological Classification of Tumors. Geneva: WHO, 1967.
27. Saccomanno, G., Saunders, R. P., and Ellis, H. Concentration of carcinoma or atypical cells in sputum. Acta Cytol., 7: 305-310, 1963.
28. Mulshine, J. L., Cuttitta, F., Bibro, M., Fedorko, J., Fargion, S., Little, C., Carney, D. N., Gazdar, A. F., and Minna, J. D. Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. J. Immunol., 131: 497-502, 1983.
29. Gupta, P. K., Myers, J. D., Baylin, S. B., Mulshine, J. L., Cuttitta, F., and Gazdar, A. F. Improved antigen detection in ethanol-fixed cytologic specimens. A modified avidin-biotin-peroxidase complex (ABC) method. Diagn. Cytopathol., 1: 133-136, 1985.
30. Tockman, M. S., Gupta, P. K., Pressman, N. J., and Mulshine, J. L. Considerations in bringing a cancer biomarker to clinical application. Cancer Res., 52 (Suppl.): 2711s-2718s, 1992.
31. Tockman, M. S., Gupta, P. K., Pressman, N. J., and Mulshine, J. L. Cytometric validation of immunocytochemical observations in developing lung cancer. Diagn. Cytopathol., 9: 615-622, 1993.
32. Rosen, S. T., Mulshine, J. L., Cuttitta, F., Fedorko, J., Carney, D. N., Gazdar, A. F., and Minna, J. D. Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res., 44: 2052-2061, 1984.
33. Zhou, J., Jensen, S. M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer, 14: 85-97, 1996.
34. Slaughter, D. P., Southwick, H. W., and Smejkal, W. "Field cancerizationin oral stratified squamous epithelium. Cancer (Phila.), 6: 963-968, 1953.
35. Minoo, P., Sullivan, W., Solomon, L. R., Martin, T. E., Toft, D. O., and Scott, R. E. Loss of proliferative potential during terminal differentiation coincides with the decreased abundance of a subset of heterogeneous ribonuclear proteins. J. Cell Biol., 109: 1937-1946, 1989.
36. Rabbitts, T. H., Forster, A., Larson, R., and Nathan, P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat. Genet., 4: 175-180, 1993.
37. Ichikawa, H., Shimizu, K., Hayashi, Y., and Ohki, M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res., 54: 2865-2868, 1994.
38. Sanchez-Garcia, I., and Rabbitts, T. H, Transcriptional activation by TALI and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc. Natl. Acad. Sci. USA, 91: 7869-7873, 1994.
39. Knight, J. C., Renwick, P. J., Dal Cin, P., Van Den Berghe, H., and Fletcher, C. D. M. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res., 55: 24-27, 1995.
40. Kuroda, M., Ishida, T., Honuchi, H., Kida, N., Uozaki, H., Takeuchi, H., Tsuji, K., Imamura, T., Mori, S., Machinami, R., and Watanabe, T. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma. Am. J. Pathol., 147: 1221-1227, 1995.
41. Calvio, C., Neubauer, G., Mann, M., and Lamond, A. I. Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. RNA, 1: 724-733, 1995.
42. Takimoto, M., Tomonaga, T., Matunis, M., Avigan, M., Krutzsch, H., Dreyfuss, G., and Levens, D. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promotor in vitro. J. Biol. Chem., 268: 18249-18253, 1993.
43. Tomonaga, T., and Levens, D. Activating transcription from single stranded DNA. Proc. Natl. Acad. Sci. USA, 93: 5830-5835, 1996.
44. Waterhouse, N., Kumar, S., Song, Q., Strike, P., Sparrow, L., Dreyfuss, G., Alnemri, E. S., Litwack, G., Lavin, M., and Watters, D. Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1β converting enzyme-like proteases in apoptosis. J. Biol. Chem., 271: 29335-29341, 1996.
45. McKay, S. J., and Cooke, H. hnRNP A2/B1 binds specifically to single stranded vertebrate telomeric repeat TTAGGGn. Nucleic Acids Res., 20: 6461-6464, 1992.
46. Ishikawa, F., Matunis, M. J., Dreyfuss, G., and Cech, T. R. Nuclear proteins that bind the pre-mRNA 3′ splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. Mol. Cell. Biol., 13: 4301-4310, 1993.
47. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 266: 2011-2015, 1994.
48. Bosser, R., Faura, M., Serratosa, J., Renau-Piqueras, J., Pruschy, M., and Bachs, O. Phosphorylation of rat liver heterogeneous nuclear ribonucleoproteins A2 and C can be modulated by calmodulin. Mol. Cell. Biol., 75: 661-670, 1995.
49. Lankford, S. P., Peters, K. L., and Elser, R. C. Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur. Urol., 27: 182-186, 1995.
50. Woolf, S. H. Screening for prostate cancer with prostate-specific antigen. N. Engl. J. Med., 333: 1401-1405, 1995.
51. Mulshine, J. L., Zhou, J., Treston, A. M., Szabo, E., Tockman, M. S., and Cuttitta, F. New approaches to the integrated management of early lung cancer. Med. Clin. N. Am., 11: 235-252, 1997.
52. Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P. O., Davis, R. W. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA, 93: 10614-10619, 1996.
53. Lam, S., MacAulay, C., Hung, J., LeRiche, J., Profio, A. E., and Palcic, B. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device. J. Thorac. Cardiovasc. Surg., 105: 1035-1040, 1993.
54. Marsh, B., Frost, J., and Erozan, Y. Bronchoscopic localization of radiologically occult cancer. Recent Results Cancer Res., 82: 87-89, 1982.
55. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., and Peters, L. J. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
56. Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.
57. Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Firket, P., Rosmentz, N., Clerici, M., Soresi, E., Valente, M., Belloni, P. A., and Ravasi, G. Adjuvant treatment of stage I lung cancer with high-dose Vitamin A. J. Clin. Oncol., 11: 1216-1222, 1993.
58. Mulshine, J. L., De Luca, L. M., and Dedrick, R. L. Regional delivery of retinoids: a new approach to early lung cancer intervention. In: Y. Martinet, N. Martinet, J. M. Vignaud, F. Hirsch, and J. L. Mulshine (eds). Clinical and Biological Basis of Lung Cancer Prevention. Basel: Birkhauser Verlag AG, in press, 1997.